The book ๐—ง๐—ผ๐˜„๐—ฎ๐—ฟ๐—ฑ ๐—š๐—ผ๐—ผ๐—ฑ ๐—ฆ๐—ถ๐—บ๐˜‚๐—น๐—ฎ๐˜๐—ถ๐—ผ๐—ป ๐—ฃ๐—ฟ๐—ฎ๐—ฐ๐˜๐—ถ๐—ฐ๐—ฒ Published Open Access on Springer Nature

InSilicoTrials is thrilled to announce the publication of โ€œ๐™๐™ค๐™ฌ๐™–๐™ง๐™™ ๐™‚๐™ค๐™คd ๐™Ž๐™ž๐™ข๐™ช๐™ก๐™–๐™ฉ๐™ž๐™ค๐™ฃ ๐™‹๐™ง๐™–๐™˜๐™ฉ๐™ž๐™˜๐™š โ€“ Best practices for the use of computational modelling & simulation in the regulatory process of biomedical products โ€ a crucial document guiding the use of simulation data & evidence in the regulatory process of biomedical products.

This work is the culmination of a global collaboration among in silico experts, coordinated by the In Silico World consortium, with significant contributions from the Avicenna Alliance, VPH Institute, and FDA professionals.

Published in open access by Springer Nature Group, the book is edited by Prof. Marco Viceconti and InSilicoTrialsโ€™ CEO Luca Emili, addressing the need for standardized practices within the in silico field.

Our strong belief is anchored in the insightful foreword by Pras Pathmanathan from the Office of Science and Engineering Laboratories, Center for Devices and Radiological Health at the FDA, suggesting a future where these words manifest into reality โ€œโ€ฆ ๐˜ช๐˜ต ๐˜ช๐˜ด ๐˜ฉ๐˜ฐ๐˜ฑ๐˜ฆ๐˜ฅ ๐˜ต๐˜ฉ๐˜ข๐˜ต ๐˜ต๐˜ฉ๐˜ช๐˜ด ๐˜ฃ๐˜ฐ๐˜ฐ๐˜ฌ ๐˜ธ๐˜ช๐˜ญ๐˜ญ ๐˜ด๐˜ต๐˜ช๐˜ฎ๐˜ถ๐˜ญ๐˜ข๐˜ต๐˜ฆ ๐˜ง๐˜ถ๐˜ณ๐˜ต๐˜ฉ๐˜ฆ๐˜ณ ๐˜ค๐˜ฐ๐˜ฏ๐˜ท๐˜ฆ๐˜ณ๐˜ด๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ๐˜ด ๐˜ข๐˜ฎ๐˜ฐ๐˜ฏ๐˜จ๐˜ด๐˜ต ๐˜ข๐˜ญ๐˜ญ ๐˜ด๐˜ต๐˜ข๐˜ฌ๐˜ฆ๐˜ฉ๐˜ฐ๐˜ญ๐˜ฅ๐˜ฆ๐˜ณ๐˜ด ๐˜ข๐˜ฏ๐˜ฅ ๐˜ถ๐˜ญ๐˜ต๐˜ช๐˜ฎ๐˜ข๐˜ต๐˜ฆ๐˜ญ๐˜บ ๐˜ค๐˜ฐ๐˜ฏ๐˜ต๐˜ณ๐˜ช๐˜ฃ๐˜ถ๐˜ต๐˜ฆ ๐˜ต๐˜ฐ ๐˜ต๐˜ฉ๐˜ฆ ๐˜ฅ๐˜ฆ๐˜ท๐˜ฆ๐˜ญ๐˜ฐ๐˜ฑ๐˜ฎ๐˜ฆ๐˜ฏ๐˜ต ๐˜ฐ๐˜ง ๐˜ค๐˜ฐ๐˜ฎ๐˜ฎ๐˜ถ๐˜ฏ๐˜ช๐˜ต๐˜บโ€“๐˜ข๐˜ค๐˜ค๐˜ฆ๐˜ฑ๐˜ต๐˜ฆ๐˜ฅ ๐˜Ž๐˜ฐ๐˜ฐ๐˜ฅ ๐˜š๐˜ช๐˜ฎ๐˜ถ๐˜ญ๐˜ข๐˜ต๐˜ช๐˜ฐ๐˜ฏ ๐˜—๐˜ณ๐˜ข๐˜ค๐˜ต๐˜ช๐˜ค๐˜ฆ, ๐˜ฃ๐˜ณ๐˜ช๐˜ฏ๐˜จ๐˜ช๐˜ฏ๐˜จ ๐˜”&๐˜š ๐˜ง๐˜ฐ๐˜ณ ๐˜ฎ๐˜ฆ๐˜ฅ๐˜ช๐˜ค๐˜ข๐˜ญ ๐˜ฑ๐˜ณ๐˜ฐ๐˜ฅ๐˜ถ๐˜ค๐˜ต๐˜ด ๐˜ต๐˜ฐ ๐˜ฎ๐˜ข๐˜ต๐˜ถ๐˜ณ๐˜ช๐˜ต๐˜บ.โ€ 

Please find below the bookโ€™s index and an overview of the chaptersโ€™ content: 

  1. Introduction 
  2. Theoretical Foundations of GSP 
  3. Model Development 
  4. Model Credibility 
  5. Possible Qualification Pathways for In Silico Methodologies 
  6. Possible Health Technology Assessment Pathways 
  7. Ethical Review of In Silico Methodologies 
  8. The Sponsor 
  9. The Investigator: modellers and analysts
     

Link to freely download the book: https://link.springer.com/book/10.1007/978-3-031-48284-7 

If youโ€™re seeking more details or interested in exploring how this groundbreaking publication can enhance your biosimulation strategies, donโ€™t hesitate to get in touch. Our InSilicoTrials experts are ready to assist you in understanding the implications of Good Simulation Practice (GSP) for your projects, illustrating best practices, and demonstrating use cases to maximize GSPโ€™s benefits for your drug development endeavors.

Comments are closed.
Start simulating now